NVO News

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novo Nordisk A/S (NVO) And Encourages Stockholders to Reach Out

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

Prefilled Syringes Market Analysis Report 2026-2031: Rising Self-Injection of GLP-1 Obesity Drugs, Shift to Biologic-Friendly COP Syringes, Glass Delamination Recalls in High-pH Biologics

Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

Novo Nordisk Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map

Ivim Health GLP-1 Weight Loss Program: Individualized Dosing, Pricing, and What Consumers Should Know in 2026

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)

ADOCIA Reports Fourth Quarter 2025 Financial Results and Provides a Business Update

Solve M.E. Funds GLP-1 and Immune Target Studies to Accelerate ME/CFS and Long Covid Breakthroughs

Bronstein, Gewirtz & Grossman, LLC Is Investigating Novo Nordisk A/S (NVO) And Encourages Stockholders to Connect